



## General description

Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis. It is used in the treatment of vascular eye diseases and in treatment protocols for some cancers.

|                    |  |
|--------------------|--|
| INN                | Bevacizumab  |
| ATC codes          | S01LA08  |
| Medicine type      | Biological agent   |
| EML status history | First added in 2013 (TRS 985) for <a href="#">Age related macular degeneration</a> |
| Wikipedia          | <a href="#">Bevacizumab</a>  |
| DrugBank           | <a href="#">Bevacizumab</a>  |

## Recommendations

Section [Ophthalmological preparations > Anti-vascular endothelial growth factor \(VEGF\) preparations](#)

[Parenteral > Locoregional injections > Intravitreal: 25 mg per mL](#)

### Indications

Age related macular degeneration

